September 3, 2013
Nuvilex: To Build or To Buy
Due to the current R&D model for large pharmaceuticals, it is often cheaper and more prudent to acquire, or invest in, a younger firm, in order to gain access to its technology than build one for from scratch, as exemplified by the recent purchase of Onyx Pharmaceuticals, Inc. (NASDAQ – ONXX). by Amgen, Inc. (NASDAQ – AMGN). This recent buyout of a cancer treatment biotech by a major pharmaceutical firm bodes well for Nuvilex, Inc.’s (OTCQB – NVLX - $0.13 – Spec Buy).
On a related note, a few months ago, we published an article on Nuvilex under our Microcap Hot Topics section that touched upon a study that indicated that less than one in five biotech and pharmaceutical clinical companies are able to successfully complete Phase II clinical trials. Since that publication, we have conducted a cursory review of firms that have conducted oncology-specific trials over the past several years and have discovered that the number of successful Phase II trials in oncology is even lower than the broader group at large.
Moreover, we were surprised to see that despite their relative size, experience, and deep pockets, many large pharmaceutical and biotech giants appear to lack the innovative spark internally. Essentially, the success of these firms in clinical trials could almost be viewed as a numbers game, as these behemoths achieve success more so from the sheer number of trials in which they engage rather than innovation. If a firm has conducted 25 separate trials over a given period, it is bound to have greater success than the Firm that has conducted two.
Due to the heavy cost structure associated with these trials, and the fact that big pharma has its own cost structure that may be higher than smaller firms, in many cases, it is cheaper and more prudent to acquire, or invest in, a younger firm, in order to gain access to its technology. Not only does it usually cost less to execute a transaction of this type, but if a bigger Firm’s mandate is to enter or attempt to lead in a specific therapeutic category, clearly a business development-based transaction makes more sense than taking the years to build and develop a therapy from scratch.
Now that Nuvilex has the live-cell encapsulation platform to treat oncology rights under wraps, its profile in the biotech community has likely changed. As a result, as the Firm prepares for the final stages of clinical trials for its pancreatic cancer treatment, its profile has been raised enough to warrant much closer looks at the technology by larger players that have not succeeded in even completing Phase II trials to treat the same disease. The list is actually quite long and contains a who’s who of the pharmaceutical and biotech world. Moreover since this biologic-based delivery platform is geared to potentially be used in conjunction with pro-drugs to treat a multitude of diseases, its value may be greater than just a typical, narrow, drug-based therapy.
While it is natural for investors to interpret the value a larger firm would have on Nuvilex, the value proposition that Nuvilex offers a larger firm should not be discounted either.
For more information, refer to our previous NVLX Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com
You Might Also Like
Senior Analyst: Robert Goldman
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com